FLUIDIGM CORPORATION (NASDAQ:FLDM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
recommended to our board, and our board approved, a retention
compensation program for our Chief Executive Officer, Chief
Financial Officer, and other executive officers subject to
Section 16 of the Securities Exchange Act of 1934, as amended.
The retention program, which is structured in the same manner as
a retention program implemented for other employees, provides for
(i) a lump sum cash payment if the individual executive officer
remains employed with us through January 1, 2019 and (ii) the
grant of stock options and restricted stock units to our 2011
Equity Incentive Plan that will vest in accordance with our
standard vesting terms.
our compensation committee and board of directors for our chief
executive officer, chief financial officer, and other current
executive officers named in our most recent proxy statement were
as set forth in the table below. In his discussions with the
compensation committee and our board, our chief executive officer
elected to receive the equity compensation set forth below in
lieu of participating in the cash element of the retention
program.
|
Name
|
Potential Cash Award
|
Shares Subject to Stock Options
|
Shares Subject to Restricted Stock Units
|
||||
|
S. Christopher Linthwaite Chief Executive Officer
|
$
|
189,500
|
76,000
|
||||
|
Vikram Jog Chief Financial Officer
|
$
|
138,400
|
87,400
|
34,600
|
|||
|
Steven C. McPhail Chief Commercial Officer
|
$
|
102,800
|
51,375
|
20,550
|
|||
|
Mai-Chan (Grace) Yow Executive Vice President,
Worldwide Manufacturing |
$
|
76,300
|
48,400
|
19,500
|
|||
retention program is filed as Exhibit 10.1 to this Current Report
on Form 8-K, and the foregoing discussion of the award agreement
is qualified in its entirety by reference to the form of
agreement. The equity awards granted in connection with the
retention program are subject to the terms and conditions of our
2011 Equity Incentive Plan and the applicable forms of agreement,
which have been previously filed with the Securities and Exchange
Commission.
|
Item 9.01
|
Financial Statements and Exhibits.
|
|
Exhibit No.
|
Description
|
|
|
10.1
|
Form of Award Agreement for purposes of the Retention
Program. |
About FLUIDIGM CORPORATION (NASDAQ:FLDM)
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers. FLUIDIGM CORPORATION (NASDAQ:FLDM) Recent Trading Information
FLUIDIGM CORPORATION (NASDAQ:FLDM) closed its last trading session down -0.10 at 5.94 with 209,669 shares trading hands.
